ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has earned a consensus recommendation of “Hold” from the six research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $16.50.
A number of equities research analysts have issued reports on ZIOP shares. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Friday, November 10th. HC Wainwright restated a “buy” rating and set a $9.50 price target on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Raymond James Financial restated a “hold” rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. BidaskClub upgraded shares of ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. Finally, ValuEngine cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st.
In other news, CEO Laurence James Neil Cooper purchased 6,440 shares of the firm’s stock in a transaction on Wednesday, November 8th. The stock was bought at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the completion of the acquisition, the chief executive officer now directly owns 1,083,731 shares of the company’s stock, valued at $5,071,861.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 10.40% of the stock is owned by corporate insiders.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.89 on Wednesday. The stock has a market cap of $694.20, a price-to-earnings ratio of -9.40 and a beta of 1.44. ZIOPHARM Oncology has a fifty-two week low of $3.77 and a fifty-two week high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. During the same quarter last year, the company earned ($0.11) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. equities analysts expect that ZIOPHARM Oncology will post -0.54 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “ZIOPHARM Oncology Inc. (ZIOP) Receives Average Recommendation of “Hold” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/24/ziopharm-oncology-inc-ziop-receives-average-recommendation-of-hold-from-analysts.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.